ASIAMEDIC LIMITED

==> picture [128 x 82] intentionally omitted <==

(Incorporated in the Republic of Singapore)

(Registration No. 197401556E)

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS AND FULL YEAR ENDED 31 DECEMBER 2025

	Page	Page
A	Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
B	Condensed Interim Statements of Financial Position	2
C	Condensed Interim Statements of Changes in Equity	3
D	Condensed Interim Consolidated Statement of Cash Flows	4
E	Notes to the Condensed Interim Consolidated Financial Statements	5
F	Information required under Appendix 7C of the Catalist Rules	13

A CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

GROUP Note Revenue N4 Other income N5.1 Consumables used Personnel expenses Depreciation of non-current assets - Plant and equipment - Right-of-use assets Maintenance equipment Laboratory and consultancy fees Facility and administrative costs Finance costs N5.1 Other operating expenses Impairment loss on financial assets - Third Party - Associate N9 Reversal of impairment loss on non- current assets, net N5.1, N8.1 Gain from deconsolidation of subsidiary N9 Gain from disposal of subsidiary N9 Share of results of associate Profit before tax N5 Income tax credit N6 Profit after tax for the period/year Attributable to: Owners of the Company Non-controlling interest Profit for the period/year, representing total comprehensive income for the period/year, attributable to owners of the Company Earnings per share for profit for the period/year attributable to the owners of the Company Basic (SGD in cent) N7 Diluted (SGD in cent) N7	6 months ended 31 December 2025 (“2H2025”) (Unaudited) 6 months ended 31 December 2024 (“2H2024”) (Unaudited) Increase (Decrease) Financial year ended 31 December 2025 (“FY2025”) (Unaudited) Financial Year ended 31 December 2024 (“FY2024”) (Audited) Increase (Decrease) $ $ % $ $ % 18,605,763 15,754,244 18% 35,221,232 28,914,624 22% 463,681 275,235 68% 818,733 663,895 23% (1,085,606) (1,035,860) 5% (2,111,418) (2,048,035) 3% (8,035,316) (7,058,528) 14% (16,061,069) (14,347,307) 12% (427,151) (286,949) 49% (893,411) (691,006) 29% (985,552) (1,040,639) (5%) (2,489,380) (1,777,378) 40% (298,659) (519,667) (43%) (543,889) (1,020,974) (47%) (3,832,799) (3,663,481) 5% (7,176,455) (5,867,765) 22% (760,650) (426,342) 78% (1,475,672) (1,020,288) 45% (460,850) (324,200) 42% (912,577) (565,201) 61% (2,230,337) (1,165,390) 91% (4,213,830) (1,973,001) 114% (15,598) (14,049) 11% (12,535) (14,049) (11%) (1,030,873) - 100% (1,030,873) - 100% - 71,704 (100%) - 71,704 (100%) 1,682,784 - 100% 1,682,784 - 100% 227,600 - 100% 227,600 - 100% 229,059 179,894 27% 399,693 316,322 26%
	2,045,495 745,972 174% 1,428,933 641,541 123% - 4,177 (100%) - 4,177 (100%)
	2,045,495 750,149 173% 1,428,933 645,718 121%
	2,062,404 1,114,079 85% 2,023,801 1,009,648 100% (16,909) (363,930) (95%) (594,868) (363,930) 63%
	2,045,495 750,149 173% 1,428,933 645,718 121%
	2,062,404 1,114,079 85% 2,023,801 1,009,648 100%
	0.18 0.10 0.18 0.09 0.18 0.10 0.18 0.09

NM: Not meaningful

B CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

Group Company 31 December 2025 (Unaudited) 31 December 2024 (Audited) 31 December 2025 (Unaudited) 31 December 2024 (Audited) $ $ $ $	Group Company 31 December 2025 (Unaudited) 31 December 2024 (Audited) 31 December 2025 (Unaudited) 31 December 2024 (Audited) $ $ $ $	Group Company 31 December 2025 (Unaudited) 31 December 2024 (Audited) 31 December 2025 (Unaudited) 31 December 2024 (Audited) $ $ $ $	Group Company 31 December 2025 (Unaudited) 31 December 2024 (Audited) 31 December 2025 (Unaudited) 31 December 2024 (Audited) $ $ $ $
4,168,083 - 2,449,878 18,707,585 891,000	3,818,584 - 2,199,062 22,137,444 891,000	25,185 8,409,804 181,500 3,745,671 -	41,854 8,409,804 181,500 4,758,699 -
26,216,546	29,046,090	12,362,160	13,391,857

142,425 4,802,838 1,274,388 260,138 3,991,907 295,920 5,694,448	315,279 4,078,065 1,093,953 267,734 3,486,109 475,920 7,991,497	- - 3,634,852 48,229 3,991,907 - 741,004	- - 4,469,008 38,603 3,486,109 - 1,128,134
16,462,064	17,708,557	8,415,992	9,121,854

1,370,607 2,938,498 800,864 2,450,477	1,640,452 4,765,615 644,311 2,354,572	- 3,038,164 - 989,983	- 4,751,549 - 1,027,072
7,560,446	9,404,950	4,028,147	5,778,621
8,901,618 8,303,607 4,387,845 3,343,233
1,592,064 15,415,737 16,065	1,611,478 18,797,613 18,391	471,201 3,376,470 -	452,966 4,366,450 -
17,023,866	20,427,482	3,847,671	4,819,416
18,094,298 16,922,215 12,902,334 11,915,674

33,394,437 (2,866) (515,334) (16,823,141)	33,669,437 (2,866) (533,484) (18,846,942)	33,394,437 (2,866) 145,399 (20,634,636)	33,669,437 (2,866) 127,249 (21,878,146)
16,053,096	14,286,145	12,902,334	11,915,674
2,041,202 2,636,070 - -
18,094,298 16,922,215 12,902,334 11,915,674

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

Group Balance at 1 January 2025 Profit for the year, representing total comprehensive income for the year Cancellation/deduction of ordinary shares Grant of equity-settled share options to employees Balance at 31 December 2025 Balance at 1 January 2024 Profit for the year, representing total comprehensive income for the year Contribution from non-controlling interest Grant of equity-settled share options to employees Balance at 31 December 2024	Share capital $ 33,669,437 – (275,000) –	Attributable to equity holders of the Company Other reserves Treasury shares Accumulated losses Total Non- controlling interests Total equity $ $ $ $ $ $ (533,484) (2,866) (18,846,942) 14,286,145 2,636,070 16,922,215 – – 2,023,8012,023,801 (594,868) 1,428,933 – – – (275,000) – (275,000) 18,150 – – 18,150 – 18,150
	33,394,437	(515,334) (2,866) (16,823,141) 16,053,096 2,041,202 18,094,298
	33,669,437 – – –	(553,449) (2,866) (19,856,590)13,256,532 – 13,256,532 – – 1,009,6481,009,648 (363,930) 645,718 – – – – 3,000,000 3,000,000 19,965 – – 19,965 – 19,965
	33,669,437	(533,484) (2,866) (18,846,942) 14,286,145 2,636,070 16,922,215

Company Balance at 1 January 2025 Profit for the year, representing total comprehensive income for the year Cancellation/deduction of ordinary shares Grant of equity-settled share options to employees Balance at 31 December 2025 Balance at 1 January 2024 Profit for the year, representing total comprehensive income for the year Grant of equity-settled share options to employees Balance at 31 December 2024	Share capital Other reserves Treasury shares Accumulated losses Total $ $ $ $ $ 33,669,437 127,249 (2,866) (21,878,146) 11,915,674 – – – 1,243,510 1,243,510 (275,000) – – – (275,000) – 18,150 – – 18,150
	33,394,437 145,399 (2,866) (20,634,636) 12,902,334
	33,669,437 107,284 (2,866) (23,463,115) 10,310,740 – – – 1,584,969 1,584,969 – 19,965 – – 19,965
	33,669,437 127,249 (2,866) (21,878,146) 11,915,674

D CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

Note Cash flows from operating activities Profit before tax Adjustments: Depreciation of plant and equipment Depreciation of right-of-use assets Reversal of impairment loss on right-of-use assets Gain on modification of right-of-use assets Impairment loss on goodwill Impairment loss on financial assets – third party Impairment loss on financial assets – associate Plant and equipment written off Gain on disposal of plant and equipment Finance costs Interest income Gain from deconsolidation of subsidiary Gain from disposal of subsidiary Other income - reversal of Interest Grant of equity-settled share options to employees Amortisation of Employment Bond Share of results of associate Operating cash flows before changes in working capital Changes in working capital Inventories Trade receivables, other receivables and deposits, and prepayments Trade and other payables Contract liabilities Net cash flows from operating activities Cash flows from investing activities Interest received Investment in associate Dividend received from associate (Addition in)/redemption of investments in other financial assets Net cash outflow arising from derecognition of previous owner Proceeds from disposal of plant and equipment Purchase of plant and equipment N8.2 Purchase of medical equipment under hire purchase Net cash flows (used in)/ from investing activities Cash flows from financing activities Decrease in cash pledged as security Contribution from non-controlling interest Interest paid Payment of principal portion of borrowings Net cash flows (used in)/ from financing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year	FY2025 (Unaudited) FY2024 (Audited) $ $ 1,428,933 641,541 893,411 691,006 2,489,380 1,777,378 - (120,000) (6,337) - - 48,296 12,535 14,049 1,030,873 - 6,178 - (57,288) - 912,577 565,201 (114,019) (170,439) (1,682,784) - (227,600) - (113,038) - 18,150 19,965 - 31,226 (399,693) (316,322)
	4,191,278 3,181,901
	56,644 48,226 (3,006,225) (1,521,719) 2,066,494 991,233 570,388 (218,876)
	3,878,579 2,480,765
	114,019 172,734 (40,000) - 266,478 360,085 (505,798) 1,486,361 (211,181) - 71,834 - (2,201,985) (728,287) (474,060) (1,077,210)
	(2,980,693) 213,683
	- 87,300 - 3,000,000 (883,973) (587,193) (2,310,962) (1,807,361)
	(3,194,935) 692,746
	(2,297,049) 3,387,194 7,991,497 4,604,303
	5,694,448 7,991,497

E. NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS AND FULL YEAR ENDED 31 DECEMBER 2025

N1. Corporate information

AsiaMedic Limited (the “ Company ”) is incorporated and domiciled in Singapore and whose shares are publicly traded on the Catalist board of the Singapore Exchange Securities Trading Limited. These condensed interim consolidated financial statements for the six (6) months and the financial year ended 31 December 2025 comprise the Company and its subsidiaries (collectively, the “ Group ”).

The principal activities of the Company are those relating to investment holding and the provision of management services.

The principal activities of the Group are:

(a) Provision of diagnostic imaging and radiology services.
(b) Provision of medical wellness and health screening services.
(c) Provision of primary healthcare services.

During the financial year, the Group disposed of its 60% equity interest, representing a controlling interest, in AsiaMedic Astique The Aesthetic Clinic Pte. Ltd. (“ AATAC ”). AATAC was engaged in medical aesthetic services and products, and upon the disposal of AATAC, this activity is no longer a principal activity of the Group.

N2. Basis of preparation

The condensed interim financial statements for the six (6) months and the financial year ended 31 December 2025 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last interim financial statements for the six months ended 30 June 2025.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note N2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.

The financial statements have been prepared on a going concern basis as the management is reasonably confident that the Group will be able to pay its debts as and when they fall due as the Group is expected to be able to generate sufficient operating cash flows and will have sufficient funds for its operations.

N2.1 New and amended s tandards adopted by the Group

No new or amendment to the Singapore Financial Reporting Standards (International) has become applicable to the Group for the current reporting period/year.

N2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 31 December 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period/year in which the estimates are revised and in any future periods/years affected.

During the financial year, management reassessed the estimated useful lives of certain medical equipment and renovation assets based on technical evaluation, maintenance history and expected usage patterns.

Following this reassessment, the estimated useful life of certain medical equipment was revised from 10 years to 15 years, and renovation assets from 6 years to 10 years.

These revisions represent changes in accounting estimates in accordance with SFRS(I) 1-8 and have been applied prospectively from 1 January 2025.

The impact of these changes reduced depreciation expense by approximately $403,000 for FY2025.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

Note N8 – Impairment of plant and equipment and right-of-use assets: key assumptions underlying recoverable amounts.

Note N9 – Impairment of investment in subsidiaries and amounts due from subsidiaries: key assumptions underlying recoverable amounts.

N3. Segment and revenue information

For management purposes, the Group regards the provision of diagnostic imaging and radiology services, medical wellness and health screening services, primary healthcare services and medical aesthetic services and products (prior to the disposal of AATAC during the financial year) as a single segment. Management has not identified any business or operating units separately for purpose of making decisions about resource allocation and performance assessment.

The Group’s revenue is derived from operations located in Singapore.

N4. Disaggregation of revenue

Major service lines: Diagnostic imaging and radiology services Medical wellness and health screening services Primary healthcare services Medical aesthetic services Less: Elimination of intercompany transactions Timing of transfer of goods or services: At a point in time	Group 2H2025 2H2024 FY2025 FY2024 $ $ $ $ 12,426,079 9,168,714 23,073,995 15,920,073 5,089,843 4,950,997 9,598,994 9,577,126 1,068,453 1,246,573 2,367,504 2,386,991 867,515 1,235,680 1,675,201 2,497,541
	19,451,890 16,601,964 36,715,694 30,381,731 (846,127) (847,720) (1,494,462) (1,467,107)
	18,605,763 15,754,244 35,221,232 28,914,624
	18,605,763 15,754,244 35,221,232 28,914,624

N5. Profit before tax

N5.1 Significant items

		Group	Group
	2H2025	2H2024	FY2025	FY2024
	$	$	$	$
Income:
Other grant income	3,771	17,821	70,108	171,206
Sub-lease income	176,512	169,597	353,024	319,250
Interest income	41,176	84,817	114,019	170,439
Other income:
Reversal of prior years’ interest accrual	113,038	-	113,038	-
Gain on disposal of plant and equipment	61,680	-	61,680	-
Compensation business downtime	38,000	-	38,000	-
Government salary reimbursement	25,179	-	42,619	-
Other income	4,325	3,000	26,245	3,000
Presented in items of expenses in statement of
profit and loss:
Gain from deconsolidation of subsidiary	1,682,784	-	1,682,784	-
Gain from disposal of subsidiary	227,600	-	227,600	-
Expenses:
Interest on borrowings:
- Finance leases	379,927	335,997	809,598	559,357
- Working capital loan	66,722	12,216	74,374	27,836
Interest on reinstatement asset	14,201	(24,013)	28,604	(21,992)
Reversal of impairment loss of right-of-use assets	-	(120,000)	-	(120,000)
Impairment loss on goodwill	-	48,296	-	48,296
Impairment loss on financial asset - associate	1,030,873	-	1,030,873	-

N5.2 Related party transactions

In addition to the related party information disclosed elsewhere in the financial statements, the following significant transactions between the Group and related parties took place on terms agreed between the parties during the financial period:

		Group
	2H2025	2H2024	FY2025	FY2024
	$	$	$	$
Purchase of consumables from an associate	210,900	210,900	421,800	422,275

N6. Income tax credit

Income tax credit for FY2025 was in respect of the recognition of deferred tax assets on unabsorbed tax loss items.

N7. Earnings per share

Basic earnings per share amounts are calculated by dividing earnings for the period/year, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period/year.

There were no potential dilutive ordinary shares. Share options are not included in the calculation of the diluted earnings per share because they are anti-dilutive.

The following table reflects the share data used in the computation of earnings per share:

	Group	Group
	FY2025	FY2024
	Number of ordinary	Number of ordinary
	shares	shares
Weighted average number of ordinary shares for basic and	1,140,412,681	1,154,522,270
diluted earnings per share computation

The weighted average number of ordinary shares used in the computation of basic and diluted earnings per share for FY2025 was 1,140,412,681 shares, comprising 1,154,522,270 shares from 1 January 2025 to 8 June 2025 and 1,129,522,270 shares from 9 June 2025 to 31 December 2025, following the change in issued share capital during the financial year.

N8. Plant and equipment and right-of-use assets

During the financial year, the Group revised the estimated useful lives of certain medical equipment from 10 years to 15 years and renovation assets from 6 years to 10 years following a reassessment of their expected economic usage.

These revisions represent changes in accounting estimates and have been applied prospectively from 1 January 2025. Further details are set out in Note N2.2.

N8.1 Impairment testing

The recoverable amount of the plant and equipment and right-of-use assets is based on the value in use of a cash generating unit (“ CGU ”). Value in use was determined by discounting the future cash flows to be generated from the continuing use of the CGU. Value in use as at 31 December 2025 was determined similarly to the 31 December 2024 impairment test, and was based on the following key assumptions:

Projections for an initial 5-year period based on management budgets. Any projections beyond the 5-year period were extrapolated using a zero annual growth rate.
Pre-tax discount rate of 7.48% (2024: 8.82%).

Following management’s impairment assessment, impairment loss was written back as follows:


	FY2025	FY2024
	$	$
Right-of-use assets	-	120,000

N8.2 Purchase of plant and equipment (“PE”)

Aggregate cost of PE acquired, excluding reinstatement assets Add: Payables for PE at 1 January Less: Payables for PE at 31 December Net cash outflow for purchase of PE presented in consolidated statement of cash flows	Group FY2025 FY2024 $ $ 1,669,026 1,449,288 923,409 202,408 (390,450) (923,409)
	2,201,985 728,287

N8.3 Right-of-use assets

Group Cost: As at 1 January 2024 Additions As at 31 December 2024 and 1 January 2025 Additions/reduction/modification Derecognition for previous owner subsidiary As at 31 December 2025 Accumulated depreciation and impairment loss: As at 1 January 2024 Depreciation charge Reversal of impairment loss As at 31 December 2024 and 1 January 2025 Depreciation charge Derecognition for previous owner subsidiary As at 31 December 2025 Net book value: As at 31 December 2024 As at 31 December 2025 Company Cost: As at 1 January 2024 Additions As at 31 December 2024, 1 January 2024 and 31 December 2025 Accumulated depreciation and impairment loss: As at 1 January 2024 Depreciation charge Reversal of impairment loss As at 31 December 2024 and 1 January 2025 Depreciation charge As at 31 December 2025 Net book value: As at 31 December 2024 As at 31 December 2025	Premises Medical Equipment Total $ $ $ 13,710,266 1,880,000 15,590,266 5,644,659 9,701,805 15,346,464
	19,354,925 11,581,805 30,936,730 (122,555) (180,000) (302,555) (1,120,253) - (1,120,253)
	18,112,117 11,401,805 29,513,922
	7,079,241 62,667 7,141,908 1,481,045 296,333 1,777,378 (120,000) – (120,000)
	8,440,286 359,000 8,799,286 1,727,357 762,023 2,489,380 (482,329) – (482,329)
	9,685,314 1,121,023 10,806,337
	10,914,639 11,222,805 22,137,444
	8,426,803 10,280,782 18,707,585
	Premises $ 12,590,013 – 12,590,013 6,939,210 1,012,104 (120,000) 7,831,314 1,013,028 8,844,342 4,758,699 3,745,671

Non-cash transaction

Aggregate cost of medical equipment acquired (Utilisation of downpayment)/downpayment for medical equipment Acquired under hire purchase arrangement Payable for medical equipment at 1 January Payable for medical equipment at 31 December Net cash outflow for purchase of medical equipment presented in consolidated statement of cash flows	Group 2025 2024 $ $ - 9,701,805 - (260,000) - (7,890,535) 474,060 - - (474,060)
	474,060 1,077,210

N9. Investment in subsidiaries and amounts due from subsidiaries

The recoverable amount of the investment in subsidiaries was based on their value in use. Value in use was determined by discounting the future cash flows to be generated from the subsidiaries. Value in use as at 31 December 2025 was determined similarly to the 31 December 2024 impairment test, and was based on the following key assumptions:

Projections for an initial 5-year period based on management budgets. Any projections beyond the 5-year period were extrapolated using a zero annual growth rate.
Pre-tax discount rate of 7.48% (2024: 8.82%).

The recoverable amount of the amounts due from subsidiaries was based on the expected credit loss model. The provision rates are based on factors that affect the collectability of the amounts including the subsidiaries’ current financial position as well as the projected cash flows of the subsidiaries.

Following management’s impairment assessment, impairment loss was written back/(recognised) as follows:

			Company	Company
Impairment loss written
back/(recognised):	FY2025	FY2024	FY2025	FY2024
	$	$	$	$
Investment in subsidiary	-	-	-	100,000
Amounts due from subsidiaries	-	-	(345,506)	1,672,958

Gain on disposal of subsidiary and loan impairment

On 31 October 2025, the Group disposed of 60% of its equity interest in AsiaMedic Astique The Aesthetic Clinic Pte. Ltd. (“ AATAC ”) for a consideration of S$150,000 and subsequently lost control of AATAC. Upon loss of control, the Group derecognised the assets and liabilities of AATAC and recognised its retained 40% interest at fair value in accordance with SFRS(I) 10 Consolidated Financial Statements . The retained interest has been accounted for as an associate under SFRS(I) 1- 28 Investments in Associates and Joint Ventures . On completion of the disposal, AATAC was recognised as an associate of the Company.

In FY2025, the Group recognised a gain on disposal of subsidiary of approximately S$1.91 million, comprising a gain from deconsolidation of subsidiary of approximately S$1.7 million, and gain from disposal of subsidiary of approximately S$0.2 million, arising mainly from the derecognition of net liabilities of AATAC.

Separately, the shareholder’s loan of S$2,061,746.87 owing by AATAC to AsiaMedic Limited (“ AATAC Loan ”) was assessed for impairment in accordance with SFRS(I) 9 Financial Instruments . Based on management’s assessment of expected recoverability, an expected credit loss provision of approximately S$1.03 million (representing 50% of the outstanding loan) was recognised in profit or loss for the financial year ended 31 December 2025.

The waiver of the AATAC Loan is subject to post-completion conditions and such conditions had not been satisfied as at 31 December 2025. Accordingly, the AATAC Loan continues to be recognised in the Company’s financial statements as at that date.

After taking into account the impairment provision, the net gain arising from the disposal recognised in profit or loss amounted to approximately S$0.88 million.


	31.12.2025	31.12.2024
	$	$
Amount due from associate	1,030,873	-

N10. Borrowings

Current Hire-purchase loans (secured) Term loan Lease liabilities Non-current Hire-purchase loans (secured) Term loan Lease liabilities Total	Group Company 31.12.2025 31.12.2024 31.12.2025 31.12.2024 $ $ $ $ 807,671 481,116 – – 187,000 204,000 – – 1,455,806 1,669,456 989,983 1,027,072
	2,450,477 2,354,572 989,983 1,027,072
	7,502,333 8,489,515 – – – 187,000 – – 7,913,404 10,121,098 3,376,470 4,366,450
	15,415,737 18,797,613 3,376,470 4,366,450

	17,866,214 21,152,185 4,366,453 5,393,522

As at 31 December 2025, the hire-purchase loan is secured by medical equipment with net carrying amount of $10,280,781 (2024:$11,222,805) and corporate guarantee by the Company.

The Company provided a corporate guarantee for the term loan.

Reconciliation of liabilities arising from financing activities:

Group Hire-purchase loans (secured) Term loan Lease liabilities Total 2025	Non-cash changes At beginning of the financial year 01.01.2025 Principal and interest payments Purchase of medical equipment under hire purchase Modification during the financial year Interest expense At end of the financial year 31.12.2025 $ $ $ $ $ $ 8,970,631 (798,720) - (180,000) 318,090 8,310,001 391,000 (278,374) - - 74,374 187,000 11,790,554 (2,117,841) - (795,009) 491,509 9,369,213
	21,152,185 (3,194,935) - (975,009) 883,973 17,866,214

Group
Hire-purchase loans
(secured)
Term loan
Lease liabilities
Total 2025

Non-cash changes
At
beginning
of the
financial
year
01.01.2025
Principal
and
interest
payments
Purchase of
medical
equipment
under hire
purchase
Modification
during the
financial
year
Interest
expense
At end of
the
financial
year
31.12.2025
$
$
$
$
$
$
8,970,631
(798,720)
-
(180,000)
318,090
8,310,001
391,000
(278,374)
-
-
74,374
187,000
11,790,554 (2,117,841)
-
(795,009)
491,509
9,369,213

21,152,185 (3,194,935)
-
(975,009)
883,973 17,866,214

Group Hire-purchase loans (secured) Term loan Lease liabilities Total 2024	Non-cash changes At beginning of the financial year 01.01.2024 Principal and interest payments Purchase of medical equipment under hire purchase Addition during the financial year Interest expense At end of the financial year 31.12.2024 $ $ $ $ $ $ 1,460,063 (477,322) 7,890,535 - 97,355 8,970,631 595,000 (231,836) - - 27,836 391,000 7,369,289 (1,685,396) - 5,644,659 462,002 11,790,554
	9,424,352 (2,394,554) 7,890,535 5,644,659 587,193 21,152,185

Group
Hire-purchase loans
(secured)
Term loan
Lease liabilities
Total 2024

Non-cash changes
At
beginning
of the
financial
year
01.01.2024
Principal
and
interest
payments
Purchase
of medical
equipment
under hire
purchase
Addition
during the
financial
year
Interest
expense
At end of the
financial
year
31.12.2024
$
$
$
$
$
$
1,460,063
(477,322)
7,890,535
-
97,355
8,970,631
595,000
(231,836)
-
-
27,836
391,000
7,369,289
(1,685,396)
-
5,644,659
462,002
11,790,554

9,424,352
(2,394,554)
7,890,535
5,644,659
587,193
21,152,185

Details of any collateral:

(a) The hire-purchase is secured by the asset financed and a corporate guarantee from the Company. (b) The term loan is secured by a corporate guarantee from the Company.

N11. Share capital

As at 1 January Movement during the year As at 31 December	Group and Company FY2025 FY2024 No. of shares $ No. of shares $ 1,154,622,270 33,669,437 1,154,622,270 33,669,437 (25,000,000) (275,000) -- --
	1,129,622,270 33,394,437 1,154,622,270 33,669,437

As at 31 December 2025, the number of ordinary shares in issue was 1,129,522,270, excluding 100,000 treasury shares (31 December 2024: 1,154,522,270 ordinary shares, excluding 100,000 treasury shares).

The Company’s subsidiaries do not hold any shares in the Company as at 31 December 2025 and 31 December 2024.

N12. Treasury shares

As at 1 January and 31 December	Group and Company FY2025 FY2024 No. of shares $ No. of shares $ 100,000 2,866 100,000 2,866

N13 Earnings before interest, tax, depreciation and amortisation (“EBITDA”)

Profit after tax Add back: Depreciation of non-current assets: - Plant and equipment - Right-of-use-assets Finance costs Income tax Less: Interest income EBITDA EBITDA attributable to the owners of the Company	FY2025 FY2024 1,428,933 645,718 893,411 691,006 2,489,380 1,777,378 912,577 565,201 – (4,177) (114,019) (170,439)
	5,610,282 4,436,531 3,504,687 3,489,327

F INFORMATION REQUIRED UNDER APPENDIX 7C OF THE CATALIST RULES

The following disclosures are in accordance with Appendix 7C Financial Statements and Dividend Announcement of the Listing Manual Section B: Rules of Catalist (the “Catalist Rules”) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and do not form part of the condensed interim financial statements set out on pages 1 to 10 of this announcement.

1. (a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to paragraph A.

(a)(ii) Significant items

Please refer to Note N5.1.

(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

Please refer to paragraph B.

(b)(ii) Aggregate amount of group's borrowings and debt securities.

Please refer to Note N10.

(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to paragraph D.

(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Please refer to paragraph C.

(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

As of 31 December 2025, there were outstanding employees share options for conversion into 50,819,677 (31 December 2024: 55,819,677) ordinary shares. Save for the above, the Company does not have any outstanding convertibles as at 31 December 2025 and 31 December 2024.

As of 31 December 2025, the number of ordinary shares in issue was 1,129,522,270, excluding 100,000 treasury shares (31 December 2024: 1,154,522,270 ordinary shares, excluding 100,000 treasury shares). The issued share capital as at 31 December 2025 was $33,394,437 (31 December 2024: $33,669,437).

The change in issued share capital and number of ordinary shares in issue is attributed to the selective capital reduction exercise to cancel 25,000,000 issued scrip shares in the capital of the Company effective from 9 June 2025, further details of which can be found in the Company’s circular to shareholders dated 2 April 2025 and approved by shareholders at the Annual General Meeting held on 29 April 2025

The 100,000 treasury shares represent 0.009% of the total number of ordinary shares in issue as at 31 December 2025 and 31 December 2024.

(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

	As at 1 January 2024	Share buyback	Sales	Transfers	Disposal	Cancellation or use	As at 31 December 2024
Number of treasury shares	100,000	–	–	–	–	–	100,000

(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. The Company does not have subsidiary holdings during and as at the end of FY2025.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by the Company’s auditor.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Please refer to Note N2.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Please refer to Note N2.1.

6. Earnings per ordinary share of the Group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

Please refer to consolidated statement of profit or loss and Note N7.

		FY2025	FY2024
		SGD cent	SGD cent
(a)	Based on weighted average number of ordinary shares on issue	0.177	0.087
(b)	On a fully diluted basis	0.179	0.087

Notes:

(a) The basic earnings per share for the year ended 31 December 2025 is computed based on weighted average share capital of 1,140,412,681 (31 December 2024:1,154,522,270) ordinary shares.
(b) There were no dilutive potential ordinary shares.

7. Net asset value (for the issuer and Group) per ordinary share based on issued share capital excluding treasury shares of the issuer at the end of the: (a) current financial period reported on; and (b) immediately preceding financial year

	Group	Group	Company	Company
	31 December	31 December	31 December	31 December
	2025	2024	2025	2024
	SGD cents	SGD cent	SGD cent	SGD cent
Net asset value per ordinary share	1.42	1.24	1.14	1.03

The total number of ordinary shares used for the computation of net asset value per share is 1,129,522,270, excluding 100,000 treasury shares (31 December 2024: 1,154,522,270 ordinary shares, excluding 100,000 treasury shares).

8. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group’s business. It must include a discussion of the following: (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

2H2025 vs 2H2024

The Group recorded revenue of $18.6 million in 2H2025, representing an increase of $2.9 million (18%) compared to $15.8 million in 2H2024. The growth was primarily driven by higher contributions from diagnostic imaging services, which increased by $3.2 million (35%) from $9.2 million in 2H2024 to $12.4 million in 2H2025. The increase was supported by higher patient volumes and the continued ramp-up of the diagnostic imaging centre at Royal Square Medical Centre Novena. Diagnostic imaging remained the Group’s largest revenue contributor during the period.

The above increase was partly offset by lower contributions from medical aesthetic services following the disposal of the Group’s 60% equity interest in AATAC on 31 October 2025, as well as from primary healthcare services. Revenue from medical aesthetic services decreased by $0.4 million, or approximately 30%, from $1.2 million in 2H2024 to $0.9 million in 2H2025, as the Group deconsolidated AATAC upon completion of the disposal on 31 October 2025.

Other income increased by $0.2 million (68%) to $0.5 million in 2H2025, mainly attributable to a reversal of prior year’s interest accrual of $0.1 million and gain on disposal of plant and equipment of $0.1 million in 2H2025.

Operational costs increased broadly in line with business expansion. Personnel expenses increased by $1.0 million (14%) to $8.0 million, reflecting manpower additions to support increased imaging capacity and operations at Royal Square Medical Centre Novena. Laboratory and consultancy fees increased by $0.2 million (5%) to $3.8 million, largely in line with higher imaging volumes and collaboration with third-party service providers.

Facility and administrative costs rose by $0.3 million (78%) to $0.8 million, mainly due to higher administrative and service charges arising from business partnership arrangements with external healthcare providers, under which referral and collaboration activities increased during 2H2025 compared to 2H2024. Finance costs increased by $0.1 million (42%) to $0.5 million, primarily reflecting the full-year recognition of interest expenses on borrowings and lease liabilities, as the related financing arrangements had only commenced progressively during FY2024.

Depreciation of plant and equipment increased by $0.1 million (49%), reflecting additional capital expenditure on medical equipment. Depreciation of right-of-use assets slightly decreased by 5% due mainly to modification of right-of-use assets.

Maintenance equipment expenses decreased by $0.2 million (43%) to $0.3 million, primarily due to the reclassification of certain IT and software-related maintenance costs to other operating expenses compared with 2H2024. Correspondingly, other operating expenses increased by $1.1 million (91%) to $2.2 million, driven by full-year operations of the diagnostic imaging centre at Royal Square Medical Centre Novena in 2H2025.

The Group recognised the extraordinary net gain of $0.9 million during 2H2025 from the Group’s disposal of 60% interest in AATAC, completed in October 2025. Please refer to Note N9 and paragraph 21 of this announcement for further details.

Share of results from associate relates to Positron Tracers Pte Ltd (“ PTPL ”) and AATAC (upon completion of the Group’s disposal of 60% interest of AATAC in October 2025) which increased by 27% to $0.2 million, mainly resulting from improved performance of PTPL and contribution from AATAC in 2H2025.

As a result of the above, profit before tax increased significantly to $2.0 million in 2H2025 (2H2024: $0.7 million), representing an increase of 174%. Profit after tax rose correspondingly to $2.0 million, compared to $0.8 million in 2H2024.

Overall, 2H2025 reflects strong operational performance supported by higher revenue, cost discipline in selected areas, and the positive impact of the one-off extraordinary gains.

FY2025 vs FY2024

The Group recorded revenue of $35.2 million in FY2025, representing an increase of $6.3 million (22%) compared to $28.9 million in FY2024. The improvement was mainly driven by an increase of $7.2 million in revenue from the diagnostic imaging services, the Group’s largest revenue contributor, which grew significantly during the year supported by higher patient volumes, expanded operating capacity and contributions from the diagnostic imaging centre at Royal Square Medical Centre Novena. As a result, diagnostic imaging services accounted for a larger proportion of the Group’s overall revenue in FY2025.

Revenue from medical wellness and health screening services remained broadly stable at $9.6 million in FY2025, reflecting sustained demand for preventive healthcare services. Revenue from medical aesthetic services decreased by $0.8 million in FY2025, mainly due to the Group’s disposed of 60% equity interest in AATAC on 31 October 2025, following which the results of the business were consolidated only up to the date of disposal. Revenue from primary healthcare services remained relatively stable at $2.4 million in FY2025.

Overall, the Group’s revenue growth in FY2025 was primarily attributable to the continued expansion and strengthening of its imaging business, which remains the key driver of the Group’s operating performance.

Other income increased by $0.2 million (23%) to $0.8 million, primarily driven by a reversal of prior year’s interest accrual of $0.1 million and gain on disposal of plant and equipment of $0.1 million, partly offset by lower grant income in FY2025 as compared to FY2024.

Operating expenses increased in line with business expansion. Personnel expenses rose by $1.7 million (12%) to $16.1 million, reflecting workforce expansion to support higher service volumes and operations at the centre at Royal Square Medical Centre Novena. Laboratory and consultancy fees increased by $1.3 million (22%) to $7.2 million, largely in line with increased diagnostic imaging activities and collaboration with third-party service providers.

Depreciation of plant and equipment increased by 29%, reflecting additional capital expenditure on medical equipment. During the year, the Group reassessed the estimated useful life of certain medical equipment, resulting in a reduction in depreciation expense of approximately $0.4 million for FY2025 (see Note N2.2). Depreciation of right-of-use assets increased by 40% due to machines’ lease recognition and rental commitments associated with expanded facilities.

Maintenance equipment costs decreased by 47% to $0.5 million, mainly due to the reclassification of certain IT and software-related maintenance expenses to other operating expenses. Facility and administrative expenses increased by 45% to $1.5 million, in line with higher operating activities and expanded business operations during the year.

Finance costs increased by 61% to $0.9 million, primarily due to higher interest expenses on equipment financing and lease liabilities under SFRS(I) 16.

The Group recognised the extraordinary net gain of approximately $0.9 million during FY2025 from the Group’s disposal of 60% interest in AATAC completed in October 2025. Please refer to Note N9 and paragraph 21 of this announcement for further detail.

Share of results from associate increased by 26% to $0.4 million, reflecting improved performance of PTPL and contribution of AATAC as an associate subsequent to the deconsolidation of the business in October 2025.

Accordingly, profit after tax increased to approximately $1.43 million in FY2025 (FY2024: $0.65 million). Excluding one-off extraordinary gain, the improvement in profit was mainly attributable to higher revenue and operating leverage from increased service volumes. Profit for the year, including non-controlling interests, rose from $1.0 million in FY2024 to $2.0 million in FY2025.

Condensed Interim Statements of Financial Position

31 December 2025 vs 31 December 2024

Non-Current Assets

Non-current assets decreased by $2.8 million from $29.0 million as at 31 December 2024 to $26.2 million as at 31 December 2025. The decrease was mainly attributable to lower right-of-use assets, which declined to $18.7 million (FY2024: $22.1 million) following depreciation charges during the year. This was partially offset by an increase in investment in associate to $2.4 million (FY2024: $2.2 million), reflecting the Group’s share of profits recognised during the year, as well as additional plant and equipment acquisitions.

Current Assets and Current Liabilities

Current assets decreased by $1.2 million from $17.7 million as at 31 December 2024 to $16.5 million as at 31 December 2025, mainly due to a reduction in cash and cash equivalents to $5.7 million (FY2024: $8.0 million). During the year, the Group utilised cash to settle outstanding vendor balances, while surplus funds were also placed into short-term treasury instruments, including Treasury bills and non-callable bank deposits presented under other financial assets. Trade receivables increased in line with higher revenue and business activity during FY2025.

Correspondingly, current liabilities decreased by $1.8 million from $9.4 million to $7.6 million, driven by lower trade payables and other payables and accruals following payments made to suppliers and service providers during the year. Contract liabilities and short-term borrowings increased marginally in the normal course of operations.

These movements reflect higher operating activity during the year, with increased receivables arising from revenue growth alongside the settlement of prior-period obligations.

Net Current Assets

Net current assets increased to $8.9 million as at 31 December 2025 compared to $8.3 million in FY2024, reflecting the settlement of outstanding payables during the year alongside higher trade receivables arising from increased revenue.

Non-Current Liabilities

Non-current liabilities decreased from $20.4 million as at 31 December 2024 to $17.0 million as at 31 December 2025, mainly due to a reduction in borrowings following higher loan repayments during the year. The increased repayments were in line with the commencement of operations at Royal Square Medical Centre Novena, for which financing had previously been obtained. Provisions for reinstatement obligations and deferred tax liabilities remained relatively stable.

Non-controlling interest

Non-controlling interests decreased from $2.6 million to $2.0 million as at 31 December 2025, mainly reflecting the share of results attributable to non-controlling shareholders during the year.

Condensed Interim Consolidated Statement of Cash Flows

Net cash generated from operating activities increased to $3.9 million in FY2025 (FY2024: $2.5 million), reflecting improved operating performance and cash generation from core operations. Net cash used in investing activities amounted to $3.0 million, mainly relating to capital expenditure on plant and medical equipment and placements into short-term Treasury bills as part of treasury management.

Net cash used in financing activities of $3.2 million was primarily attributable to scheduled repayment of borrowings and interest payments following the commencement of operations at Royal Square Medical Centre Novena. Consequently, cash and cash equivalents stood at $5.7 million as at 31 December 2025 (FY2024: $8.0 million), reflecting the Group’s deployment of cash towards operational expansion and debt servicing while continuing to generate positive operating cash flows.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

The healthcare and diagnostic imaging industry in Singapore continues to benefit from favourable long-term fundamentals driven by an ageing population, growing healthcare awareness, and increasing demand for preventive healthcare and diagnostic services. However, the operating environment remains competitive, with ongoing challenges relating to manpower shortages, rising labour costs and increasing operating expenses across the healthcare sector.

During FY2025, the Group expanded its diagnostic imaging capacity with the commencement of operations at Royal Square Medical Centre Novena, which complements the Group’s existing integrated medical centre at Orchard Road. The additional capacity positions the Group to meet growing demand from specialist clinics, hospitals and corporate healthcare providers, while strengthening its presence in key medical hubs in Singapore.

Following the operational ramp-up of our operations at Royal Square Medical Centre Novena, the Group expects to focus on improving operational efficiency, optimising utilisation rates and enhancing service delivery to support sustainable performance over the next 12 months. Continued investment in technology, workflow optimisation and talent development remains necessary amid competition for skilled healthcare professionals.

Industry trends towards preventive healthcare, employee wellness programmes and national health promotion initiatives are expected to continue supporting demand for the Group’s health screening and wellness services. Government-led healthcare initiatives and increasing emphasis on early detection are anticipated to contribute positively to service volumes in the coming periods.

The Group expects lower contribution from its On-site healthcare services segment in the next reporting period following the conclusion of the Health Promotion Board (“ HPB ”) school health screening project, for which the Company was not awarded the subsequent tender announced in late 2025. While the project contributed positively in prior periods, management continues to explore alternative on-site healthcare opportunities and corporate screening engagements to support segment performance

Looking ahead, the Group will continue to strengthen strategic partnerships and explore opportunities to expand integrated healthcare services while maintaining prudent cost management and operational discipline. While cost pressures and competitive dynamics are expected to persist, management remains cautiously optimistic about the Group’s prospects for the next reporting period and the next 12 months.

11. Dividend information.

a) Whether an interim (final) ordinary dividend has been declared (recommended).

No

b) (1) Amount per share: N/A
(2) Previous corresponding period: Nil cents
c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

N/A

d) The date the dividend is payable: NA
e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.

N/A

12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

No dividend has been declared or recommended for FY2025 as the Company remains in an accumulated losses position. The Board intends to conserve cash to support business expansion, debt servicing and working capital requirements, and will review the Company’s dividend policy when the accumulated losses position is addressed.

13. If the group has obtained general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920 (1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company does not have a general mandate for interested person transactions.

14. Negative confirmation pursuant to Rule 705(5).

This section is not applicable for announcement of full year results.

15. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720.

The Company has received undertaking from all its Directors and executive officers in the format as set out in Appendix 7H under Rule 720(1) of the Catalist Rules.

16. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer’s most recently audited annual financial statements, with comparative information for the immediately preceding year.

Not applicable as the Group operates in only one segment.

17. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the operating segments.

Noted. Please refer to Section 8 for the review of performance.

18. A breakdown of sales.

			Group
		FY2025	FY2024	Increase/ (Decrease)
		$	$	%
(a)	Sales reported for first half year	16,615,469	13,160,380	26%
(b)	Operating (loss)/profit after tax for the year
	before deducting non-controlling interests	(616,562)	(104,431)	nm
	reported for first half year
(c)	Sales reported for second half year	18,605,763	15,754,244	18%
(d)	Operating profit after tax for the year before
	deducting non-controlling interests reported for	2,045,495	750,149	nm
	second half year

19. A breakdown of the total annual dividend (in dollar value) for the issuer’s latest full year and its previous full year as follows.

		FY2025	FY2024
(a)	Ordinary	–	–
(b)	Preference	–	–
(c)	Total	–	–

20. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

The Company confirms that no person occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a director, chief executive officer or substantial shareholder of the Company.

21. Disclosure of acquisition (including incorporations) and sale of shares under Catalist Rule 706A.

Pursuant to Rule 706A of the Catalist Rules, the Company wishes to announce that on 31 October 2025, the Group disposed of 60% of its equity interest in AsiaMedic Astique The Aesthetic Clinic Pte. Ltd. (“ AATAC ”) for a cash consideration of S$150,000. Following the disposal, the Group retains a 40% equity interest in AATAC.

The disposal consideration was determined after taking into account the adjusted net fixed assets of AATAC of approximately S$250,000.

Save as disclosed above, there were no acquisitions or disposals of shares in any subsidiaries or associated companies of the Group during FY2025 that are required to be reported under Rule 706A of the Catalist Rules.

BY ORDER OF THE BOARD

Foo Soon Soo (Ms) Company Secretary

Singapore 1 March 2026

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “ SGX-ST ”) and the SGXST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.

AI assistant

ASIAMEDIC LIMITED — Interim / Quarterly Report 2025

67562_rns_2026-03-01_956e97eb-2018-4a36-b6ca-d188f21eff83.pdf